Chemotherapy in patients with prostate specific antigen-only disease after primary therapy for prostate carcinoma: A phase II trial of oral estramustine and oral etoposide

Cancer

Volumn 91, Issue 11, 2001, Pages 2175-2180

  Munshi, Hidayatullah G ^a   Pienta, Kenneth J ^a   Smith, David C ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Chemotherapy; Early recurrent; Estramustine; Etoposide; Leukemia; Prostate carcinoma; Thrombosis

Indexed keywords

ESTRAMUSTINE; ETOPOSIDE; PROSTATE SPECIFIC ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; THORAX PAIN; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ESTRAMUSTINE; ETOPOSIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 0035370672     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010601)91:11<2175::AID-CNCR1246>3.0.CO;2-D     Document Type: Article

References (21)

1. Landis SH, Murray T, Bolder S, Wingo PA. Cancer statistics, 1999 [see comments]. CA Cancer J Clin 1999;49:8-31.
2. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening [see comments]. JAMA 1993;270:948-54.
3. Trapasso JG, deKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy [see comments]. J Urol 1994;152:1821-5.
4. Zietman AL, Coen JJ, Dallow KC, Shipley WU. The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome [see comments]. Int J Radiat Oncol Biol Phys 1995;32:287-92.
5. Ornstein DK, Oh J, Herschman JD, Andriole GL. Evaluation and management of the man who has failed primary curative therapy for prostate cancer. Urol Clin No Am 1998;25:591-601.
6. Santen RJ. Clinical review 37: endocrine treatment of prostate cancer. J Clin Endocrinol Metab 1992;75:685-9.
7. Schroeder FH. Endocrine treatment of prostate cancer. In: Walsh PC, Retik AB, Vaughan ED, Wein EJ, editors. Campbell's urology. Vol. 3. 7th ed. Philadelphia: W.B. Saunders, 1998: 2627-44.
8. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer (published erratum appears in Prostate 1996;28:414]. Prostate 1996;28:251-65.
9. Pienta KJ. Intermediate biomarkers for monitoring the prevention and treatment of prostatic diseases. Proc Am Assoc Cancer Res 1995;36:712.
10. Pienta KJ, Redman BG, Bandekar R, Strawderman M, Cease K, Esper PS, et al. A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology 1997;50:401-6;[discussion]406-7.
11. Beedassy A, Cardi G. Chemotherapy in advanced prostate cancer. Semin Oncol 1999;26:428-38.
12. Hudes G, Einhorn L, Ross E, Balsham A, Loehrer P, Ramsey H, et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory cancer: a Hoosier Oncology Group and Fox Chase Network Phase III Trial. J Clin Oncol 1999;17:3160-6.
13. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999;17:2506-13.
14. Karr JP, Wajsman Z, Kirdani RY, Murphy GP, Sandberg AA. Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients. J Urol 1980;124:232-6.
15. Pienta KJ, Redman B, Hussain M, Cummings G, Esper PS, Appel C, et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate [see comments]. J Clin Oncol 1994;12:2005-12.
16. Pommier YG, Fesen MF, Goldwasser F. Topoisomerase II inhibitors: the epipodophyllotoxins, m-AMSA, and the ellipticine derivitives. In: Longo C, editor. Cancer chemotherapy and biotherapy: principles and practice. Philadelphia: Lippincott-Raven, 1996;435-61.
17. Katato K, Flaherty L, Varterasian M. Secondary acute myelogenous leukemia following treatment with oral etoposide [letter]. Am J Hematol 1996;53:54-5.
18. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy [see comments]. JAMA 1999;281:1591-7.
19. Byar DP. The veteran's administration cooperative urological research group's studies of cancer of the prostate. Cancer 1973;32:1126.
20. Anonymous. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 1997;79:235-46.
21. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer (see comments]. N Engl J Med 1999;341:1781-8.